Noninvasive test optimizes colon cancer screening rates, study finds

A study of nearly 6,000 North Texas patients suggests sweeping changes be made to the standard of care strategy for colorectal screenings, finding that participation rates soared depending on the screening method offered and how patient outreach was done.

The results also suggest that a noninvasive colorectal screening approach, such as a fecal immunochemical tests (FIT) might be more effective in prompting participation in potentially lifesaving among underserved populations than a colonoscopy, a more expensive and invasive procedure.

Researchers at UT Southwestern and the University of California, San Diego, have found that organized mailing campaigns offering two colorectal cancer tests increased screening rates as much as threefold among uninsured patients.

The study is available online in the Aug. 5 edition of JAMA Internal Medicine.

FIT, a quick and easy test that requires no special preparation, detects small amounts of occult (hidden) blood in a patient's stool sample. Completed tests are then mailed to a laboratory for analysis. The findings presented in the published paper showed that with the help of a mail campaign, FIT participation tripled, and colonoscopy participation doubled in the study sample.

In the investigation, uninsured patients at John Peter Smith (JPS) Health Network in Fort Worth ages 54 to 64 years and not up to date with their screenings were mailed invitations to use and return a no-cost FIT, or to schedule a no-cost colonoscopy. Both groups also received follow-up telephone calls to promote testing.

"The study suggests that the best approach to offering and delivering screening to underserved populations may be through FIT," said senior author Dr. Celette Sugg Skinner, associate director of population science and control for the Harold C. Simmons Cancer Center. "Questions for the future are whether superior participation can be maintained in the FIT group [because the test must be repeated every year] and how adherence rates will impact overall screening effectiveness and cost."

Study authors say the findings raise the possibility that cost-effective, large-scale public health efforts to boost screening may be more successful if noninvasive tests, such as FIT, are offered along with colonoscopy screenings.

add to favorites email to friend print save as pdf

Related Stories

A recipe for increased colorectal cancer screening rates

Aug 14, 2012

Screening for colorectal cancer (CRC) is cost-effective and saves lives by early detection. The ability to screen large numbers of individuals is especially important for states with tight health insurance budgets dealing ...

Colon cancer screening doubles with new e-health record use

Mar 04, 2013

Researchers used electronic health records to identify Group Health patients who weren't screened regularly for cancer of the colon and rectum—and to encourage them to be screened. This centralized, automated approach doubled ...

Recommended for you

New breast cancer imaging method promising

1 hour ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

1 hour ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

Breast cancer replicates brain development process

1 hour ago

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Is genetic instability the key to beating cancer?

3 hours ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

7 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments